Market Place
Sourcing Support
Nanoscope Therapeutics to Present Research at ASGCT 2025 Meeting
12 May 2025 //
PR NEWSWIRE
Ashish Patel, PhD, Joins Nanoscope as Senior VP of Sales
27 Mar 2025 //
PR NEWSWIRE
Ramesh Arjunji, PhD, Joins Nanoscope as EVP, Value and Access
05 Mar 2025 //
PR NEWSWIRE
Verana & Nanoscope Partner To Advance Retinitis Pigmentosa Research
25 Feb 2025 //
GLOBENEWSWIRE
Nanoscope Therapeutics to Present at BIO CEO & Investor Conference
06 Feb 2025 //
PR NEWSWIRE
Ray Kaczmarek Joins Nanoscope as Chief Technical Officer
05 Dec 2024 //
PR NEWSWIRE
Nanoscope Publishes Breakthrough On MCO-010 And Neurodegeneration
21 Oct 2024 //
PR NEWSWIRE
Nanoscope Appoints Khandan Baradaran as Sr. VP of Regulatory and Quality
14 May 2024 //
PR NEWSWIRE
Nanoscope preps filing for retinitis pigmentosa gene therapy
26 Mar 2024 //
PHARMAPHORUM
Nanoscope eyes market after phase 2b retinal disease data drop
26 Mar 2024 //
FIERCE BIOTECH
Nanoscope Therapeutics Appointed Samuel Barone, M.D., as Chief Medical Officer
21 Sep 2023 //
PR NEWSWIRE
Nanoscope Therapeutics to Present at the BIO International Convention
05 Jun 2023 //
PR NEWSWIRE
Nanoscope Therapeutics Announces Presentations at World Orphan Drug Congress
22 May 2023 //
PR NEWSWIRE
Nanoscope Announces Presentation of Key Results Ph2b RESTORE Trial of MCO-010
27 Apr 2023 //
PR NEWSWIRE
Nanoscope Announces Positive Results from Phase 2b RESTORE Trial of MCO-010
30 Mar 2023 //
PR NEWSWIRE
Nanoscope`s gene therapy boosts vision function in phase 2 test
30 Mar 2023 //
FIERCE BIOTECH
Nanoscope Appoints Industry Veteran Vicente Anido Jr. as a Strategic Advisor
20 Mar 2023 //
PR NEWSWIRE
Charles & Nanoscope Announce Multifaceted Gene Therapy Manufacturing Partnership
18 Oct 2022 //
BUSINESSWIRE
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010
10 Oct 2022 //
FIRSTWORLDPHARMA
Nanoscope Therapeutics to Present at Eyecelerator during the American Academy
26 Sep 2022 //
PRNEWSWIRE
Nanoscope concludes enrolment in Stargardt disease gene therapy trial
14 Sep 2022 //
CLINICALTRIALSARENA
Nanoscope Announces Completion of Enrollment in STARLIGHT Phase 2 of MCO-010
13 Sep 2022 //
PRNEWSWIRE
Nanoscope to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting
08 Sep 2022 //
PRNEWSWIRE
Nanoscope Announces Presentations at the 22nd Euretina Congress
29 Aug 2022 //
PRNEWSWIRE
Nanoscope Therapeutics to Present at the Retina Forum 2022
26 Aug 2022 //
PRNEWSWIRE
Nanoscope Therapeutics Appoints Two Pharmaceutical Industry Veterans
25 May 2022 //
PRNEWSWIRE
Nanoscope`s Vision Restoring Optogenetic Gene Therapy to be Featured in ARVO
26 Apr 2022 //
PRNEWSWIRE
Nanoscope Tx Completes Enrollment of Phase 2b Trial in Blind Patients
07 Feb 2022 //
PRNEWSWIRE
Nanoscope Announces FDA Clearance of IND for MCO-010 Gene Therapy
25 Jan 2022 //
PRNEWSWIRE
Nanoscope Therapeutics co-Founder and President to Present at World Orphan
15 Nov 2021 //
PRNEWSWIRE
Nanoscope President to Present at Eyecelerator during the ACO
09 Nov 2021 //
BIOSPACE
Nanoscope President to Present at Company Showcase of the OIS Retina
05 Oct 2021 //
STARLOCAL MEDIA
Nanoscope Bags $1.5M PIIb SBIR Grant for Activatable Opsin Gene Therapy in AMD
14 Sep 2021 //
PRNEWSWIRE
Nanoscope Announces Positive Results from Optogenetic Gene Therapy
08 Sep 2021 //
PRNEWSWIRE
Nanoscope`s Patient Dosed in Phase 2b clinical trial of Optogenetic Gene therapy
19 Jul 2021 //
PR NEWSWIRE
Nanoscope`s Optogenetic Gene Therapy Restores Clinically Meaningful Vision
03 Jun 2021 //
BIOSPACE
